Short answer
Design Therapeutics, Inc. (DSGN) filed its Q2 2026 10-Q quarterly report on Aug 3, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $0 with net income of −$20M.
Q2 2026 key financials · XBRL
- Revenue
- $0
- Net income
- −$20M
- −5.7% YoY · −14.3% QoQ
- EPS (diluted)
- −$0.32
- +5.9% YoY · −10.3% QoQ
Source: XBRL data from the Design Therapeutics, Inc. (DSGN) Q2 2026 10-Q on SEC EDGAR. USD.
Design Therapeutics, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No explicit new risk factor identified; section contains carried-forward risks without a stated “no material changes” disclosure
- DT-216 development shifted from DT-216P1 to DT-216P2 after injection-site thrombophlebitis in five MAD-trial patients
- FDA clinical-hold risk for DT-216P2; hold lifted December 2025 after clearance to initiate clinical studies
- Clinical-stage execution risk; DT-818 Phase 1 MAD results anticipated in 2027
- Funding risk; $207.4 million in cash, cash equivalents and investment securities expected to fund operations for more than 12 months
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Design Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.